Host Protein General Information (ID: PT0599)
  Protein Name
HUMAN la-related protein 1 (LARP1)
  Gene Name
LARP1
  Host Species
Homo sapiens
  Uniprot Entry Name
LARP1_HUMAN
  Protein Families
LARP family
  Subcellular Location
Cytoplasm Cytoplasmic granule
  External Link
NCBI Gene ID
23367
Uniprot ID
Q6PKG0
Ensembl ID
ENSG00000155506
HGNC ID
HGNC:29531
  Function in Host
RNA-binding protein that regulates the translation ofspecific target mRNA species downstream of the mTORC1 complex, infunction of growth signals and nutrient availability. Interacts on the one hand with the3' poly-A tails that are present in all mRNA molecules, and on theother hand with the 7-methylguanosine cap structure of mRNAs containinga 5' terminal oligopyrimidine (5'TOP) motif, which is present in mRNAsencoding ribosomal proteins and several components of the translationmachinery. The interactionwith the 5' end of mRNAs containing a 5'TOP motif leads totranslational repression by preventing the binding of EIF4G1. When mTORC1 is activated, LARP1 is phosphorylated and dissociates fromthe 5' untranslated region (UTR) of mRNA. Does not prevent binding of EIF4G1 to mRNAs that lacka 5'TOP motif. Interacts with the free 40S ribosomesubunit and with ribosomes, both monosomes and polysomes. Under normal nutrient availability, interacts primarily with the 3'untranslated region (UTR) of mRNAs encoding ribosomal proteins andincreases protein synthesis. Associates with actively translating ribosomes and stimulatestranslation of mRNAs containing a 5'TOP motif, thereby regulatingprotein synthesis, and as a consequence, cell growth and proliferation. Stabilizes mRNAs species with a5'TOP motif, which is required to prevent apoptosis. [1-9]
    Click to Show/Hide
  3D Structure

Function of This Protein During Virus Infection
Virus NameSARS-COV-2 Protein Function Anti-viral [10]
Infected TissueLung Infection Time24h; 48 h
Infected CellCalu-3 cells (Human lung cancer cell line) Cellosaurus IDCVCL_0609 
Method DescriptionTo detect the role of host protein LARP1 in viral infection, LARP1 protein knockout Calu-3 cells were infected with SARS-COV-2 for 24 - 48 h , and the effects on infection was detected through qRT-PCR.
ResultsIt is reported that Knockdown of LARP1 increases SARS-CoV-2 RNA levels compared with control group.

Host Protein - Virus RNA Network

 Full List of Virus RNA Interacting with This Protien
            RNA Region: 3'-UTR (hCoV-19/Not Specified Virus Strain )
              RNA Region Details RNA Info Click to show the detail information of this RNA binding region [11]
              Strains Name
hCoV-19/Not Specified Virus Strain
              RNA Binding Region
3'-UTR
              Virus Name
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
              Infection Cells Huh7 cells (human liver cell line); Calu-3 cells (human lung cancer cell line)  (CVCL_0336;CVCL_0609 )
              Cell Originated Tissue Liver; Lung
              Interaction Score P-value < 0.05
              Method Description RNA pull-down assays; liquid chromatography with tandem mass spectrometry (LC-MS/MS); Wilcoxon test; MS2 affinity purification coupled with liquid chromatography-mass spectrometry (MAMS)
           RNA Region: 5'-UTR (hCoV-19/South Korea/KCDC03/2020 )
              RNA Region Details RNA Info Click to show the detail information of this RNA binding region [10]
              Strains Name
hCoV-19/South Korea/KCDC03/2020
              Strains Family
Alpha (B.1.1.7)
              RNA Binding Region
5'-UTR
              Virus Name
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
              Interaction Type Directly bind to SARS-CoV-23 RNA's 5' UTR region
              Infection Cells Vero cells (epithelial kidney cell) Vero cells (epithelial kidney cell)  (CVCL_0059 )
              Cell Originated Tissue kidney
              Infection Time 24 h
              Interaction Score P-adjust < 0.05
              Method Description Modified RNA antisense purification coupled with mass spectrometry (RAP-MS); label-free quantification (LFQ); liquid chromatography with tandem mass spectrometry (LC-MS/MS)
           RNA Region: Not Specified Virus Region (hCov-OC43/VR-759 Quebec/2019 )
              RNA Region Details RNA Info Click to show the detail information of this RNA binding region [10]
              Strains Name
hCov-OC43/VR-759 Quebec/2019
              Strains Family
Beta
              RNA Binding Region
Not Specified Virus Region
              Virus Name
Human coronavirus OC43 (HCov-OC43)
              Infection Cells HCT-8 cells (Human ileocaecal adenocarcinoma cell) HCT-8 cells (Human ileocaecal adenocarcinoma cell)  (CVCL_2478 )
              Cell Originated Tissue Ileocecum
              Infection Time 12h; 24; 36h; 48h
              Interaction Score p_value < 0.05; FDR < 10%
              Method Description Modified RNA antisense purification coupled with mass spectrometry (RAP-MS); label-free quantification (LFQ); liquid chromatography with tandem mass spectrometry (LC-MS/MS)
           RNA Region: Not Specified Virus Region (hCoV-19/Not Specified Virus Strain )
              RNA Region Details RNA Info Click to show the detail information of this RNA binding region [12]
              Strains Name
hCoV-19/Not Specified Virus Strain
              RNA Binding Region
Not Specified Virus Region
              Virus Name
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
              Infection Cells Huh7 cells (liver carcinoma cell) Huh7 cells (liver carcinoma cell)  (CVCL_0336 )
              Cell Originated Tissue Liver
              Infection Time 24h
              Interaction Score log2FC = 4.01006E+14
              Method Description RNA antisense purification and quantitative mass spectrometry (RAP-MS); Tandem mass tag (TMT) labelling; liquid chromatography tandem mass spectrometry (LC-MS/MS); Westernblot
           RNA Region: Not Specified Virus Region (hCoV-19/England/02/2020 )
              RNA Region Details RNA Info Click to show the detail information of this RNA binding region [13]
              Strains Name
hCoV-19/England/02/2020
              Strains Family
Beta (B.1.351)
              RNA Binding Region
Not Specified Virus Region
              Virus Name
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
              Infection Cells Calu-3 cells (Human lung cancer cell) Calu-3 cells (Human lung cancer cell)  (CVCL_0609 )
              Cell Originated Tissue Lung
              Infection Time 24 h
              Interaction Score P-adjust = 0.008
              Method Description UV protein-RNA crosslinking; RNA interactome capture (cRIC); RNA antisense purification coupled with mass spectrometry (RAP-MS)

Differential Gene Expression During SARS-COV-2 Infection
GEO Accession: GSE152641
Sample Type: Blood
Samples Details: Healthy Control: 24; COVID-19: 62
Platform: GPL24676 Illumina NovaSeq 6000
Picture Not Found

GEO Accession: GSE162835
Sample Type: Nasopharyngeal Swabs
Samples Details: COVID-19 (Mild Symptoms): 37; COVID-19 (Moderate Symptoms): 10; COVID-19 (Severe Symptoms): 3
Platform: GPL24676 Illumina NovaSeq 6000
Picture Not Found

GEO Accession: GSE175779
Sample Type: Human Bronchial Epithelial Cells
Samples Details: Healthy Control: 4 (0, 24, 48, 72 and 96 h); COVID-19: 4 (24, 48, 72 and 96 h)
Platform: GPL18573 Illumina NextSeq 500
Picture Not Found

Protein Phosphorylation after Virus Infection
S1040 [14]
Picture Not Found
S1056 [14]
Picture Not Found
S143 [14]
Picture Not Found
S220 [14]
Picture Not Found
S517 [14]
Picture Not Found
S521 [15]
Picture Not Found
S521 [14]
Picture Not Found
S546 [15]
Picture Not Found
S546 [14]
Picture Not Found
S548 [15]
Picture Not Found
S548 [14]
Picture Not Found
S75 [14]
Picture Not Found
S766 [15]
Picture Not Found
S766 [14]
Picture Not Found
S774 [15]
Picture Not Found
S774 [14]
Picture Not Found
S823 [14]
Picture Not Found
S824 [15]
Picture Not Found
S824 [14]
Picture Not Found
S830 [14]
Picture Not Found
S847 [14]
Picture Not Found
S849 [14]
Picture Not Found
S853 [14]
Picture Not Found
S90 [14]
Picture Not Found
T1071 [15]
Picture Not Found
T1071 [14]
Picture Not Found
T1074 [14]
Picture Not Found
T137 [14]
Picture Not Found
T138 [14]
Picture Not Found
T376 [14]
Picture Not Found
T515 [14]
Picture Not Found
T526 [15]
Picture Not Found
T526 [14]
Picture Not Found
T647 [14]
Picture Not Found
T649 [15]
Picture Not Found
T649 [14]
Picture Not Found
T724 [14]
Picture Not Found
T769 [14]
Picture Not Found
T865 [14]
Picture Not Found

Potential Drug(s) that Targets This Protein
Drug Name DrunkBank ID Pubchem ID TTD ID REF
(-)-Rapamycin DB12017  . D0V15HJ  [16]
Rapamycin DB12016  . D0V14HJ  [16]
Sapanisertib DB11836  45375953  D03DPZ  [17]
Sapanisertib DB12015  . D0V13HJ  [16]
SIROLIMUS DB00877  5284616  D03LJR  [17]
Ulocuplumab DB12018  . D0V16HJ  [16]
Ulocuplumab DB12018  . D0V16HJ  [16]

Protein Sequence Information
MATQVEPLLPGGATLLQAEEHGGLVRKKPPPAPEGKGEPGPNDVRGGEPDGSARRPRPPCAKPHKEGTGQQERESPRPLQLPGAEGPAISDGEEGGGEPGAGGGAAGAAGAGRRDFVEAPPPKVNPWTKNALPPVLTTVNGQSPPEHSAPAKVVRAAVPKQRKGSKVGDFGDAINWPTPGEIAHKSVQPQSHKPQPTRKLPPKKDMKEQEKGEGSDSKESPKTKSDESGEEKNGDEDCQRGGQKKKGNKHKWVPLQIDMKPEVPREKLASRPTRPPEPRHIPANRGEIKGSESATYVPVAPPTPAWQPEIKPEPAWHDQDETSSVKSDGAGGARASFRGRGRGRGRGRGRGRGGTRTHFDYQFGYRKFDGVEGPRTPKYMNNITYYFDNVSSTELYSVDQELLKDYIKRQIEYYFSVDNLERDFFLRRKMDADGFLPITLIASFHRVQALTTDISLIFAALKDSKVVEIVDEKVRRREEPEKWPLPPIVDYSQTDFSQLLNCPEFVPRQHYQKETESAPGSPRAVTPVPTKTEEVSNLKTLPKGLSASLPDLDSENWIEVKKRPRPSPARPKKSEESRFSHLTSLPQQLPSQQLMSKDQDEQEELDFLFDEEMEQMDGRKNTFTAWSDEESDYEIDDRDVNKILIVTQTPHYMRRHPGGDRTGNHTSRAKMSAELAKVINDGLFYYEQDLWAEKFEPEYSQIKQEVENFKKVNMISREQFDTLTPEPPVDPNQEVPPGPPRFQQVPTDALANKLFGAPEPSTIARSLPTTVPESPNYRNTRTPRTPRTPQLKDSSQTSRFYPVVKEGRTLDAKMPRKRKTRHSSNPPLESHVGWVMDSREHRPRTASISSSPSEGTPTVGSYGCTPQSLPKFQHPSHELLKENGFTQHVYHKYRRRCLNERKRLGIGQSQEMNTLFRFWSFFLRDHFNKKMYEEFKQLALEDAKEGYRYGLECLFRYYSYGLEKKFRLDIFKDFQEETVKDYEAGQLYGLEKFWAFLKYSKAKNLDIDPKLQEYLGKFRRLEDFRVDPPMGEEGNHKRHSVVAGGGGGEGRKRCPSQSSSRPAAMISQPPTPPTGQPVREDAKWTSQHSNTQTLGK
    Click to Show/Hide

References
1 Autogenous Control of 5 TOP mRNA Stability by 40S Ribosomes. Mol Cell. 2017 Jul 6;67(1):55-70.e4.
2 Proteomic analysis of cap-dependent translation identifies LARP1 as a key regulator of 5 TOP mRNA translation. Genes Dev. 2014 Feb 15;28(4):357-71.
3 La-related protein 1 (LARP1) repression of TOP mRNA translation is mediated through its cap-binding domain and controlled by an adjacent regulatory region. Nucleic Acids Res. 2018 Feb 16;46(3):1457-1469.
4 LARP1 functions as a molecular switch for mTORC1-mediated translation of an essential class of mRNAs. Elife. 2017 Jun 26;6:e25237.
5 La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs. Elife. 2017 Apr 7;6:e24146.
6 The La-related protein 1-specific domain repurposes HEAT-like repeats to directly bind a 5 TOP sequence. Nucleic Acids Res. 2015 Sep 18;43(16):8077-88.
7 La-related Protein 1 (LARP1) Represses Terminal Oligopyrimidine (TOP) mRNA Translation Downstream of mTOR Complex 1 (mTORC1). J Biol Chem. 2015 Jun 26;290(26):15996-6020.
8 LARP1 specifically recognizes the 3 terminus of poly(A) mRNA. FEBS Lett. 2013 Jul 11;587(14):2173-8.
9 The RNA binding protein Larp1 regulates cell division, apoptosis and cell migration. Nucleic Acids Res. 2010 Sep;38(16):5542-53.
10 The SARS-CoV-2 RNA interactome. Mol Cell. 2021 Jul 1;81(13):2838-2850.e6.
11 Mapping the host protein interactome of non-coding regions in SARS-CoV-2 genome. bioRxiv. 2021 Jun; DOI:10.1101/2021.06.19.449092.
12 The SARS-CoV-2 RNA-protein interactome in infected human cells. Nat Microbiol. 2021 Mar;6(3):339-353.
13 Global analysis of protein-RNA interactions in SARS-CoV-2-infected cells reveals key regulators of infection. Mol Cell. 2021 Jul 1;81(13):2851-2867.e7.
14 Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. Nature. 2021 Jun;594(7862):246-252.
15 The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell. 2020 Aug 6;182(3):685-712.e19.
16 A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. bioRxiv. 2020 Mar 22;2020.03.22.002386.
17 A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020 Jul;583(7816):459-468.